Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Antioxidants in brain tumors: current therapeutic significance and future prospects.

Tytuł:
Antioxidants in brain tumors: current therapeutic significance and future prospects.
Autorzy:
Qi X; Department of Neurosurgery, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang, China.; Department of Neurosurgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310020, Zhejiang, China.
Jha SK; Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, Uttar Pradesh, 201310, India. .; Department of Biotechnology Engineering and Food Technology, Chandigarh University, Mohali, 140413, India. .; Department of Biotechnology, School of Applied & Life Sciences (SALS), Uttaranchal University, Dehradun, 248007, India. .
Jha NK; Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, Uttar Pradesh, 201310, India.
Dewanjee S; Advanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, 700032, India.
Dey A; Department of Life Sciences, Presidency University, 86/1 College Street, Kolkata, West Bengal, 700032, India.
Deka R; Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, Uttar Pradesh, 201310, India.
Pritam P; Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, Uttar Pradesh, 201310, India.
Ramgopal K; Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, Uttar Pradesh, 201310, India.
Liu W; School of Nursing, Anhui University of Chinese Medicine, Hefei, 230001, Anhui, China. .
Hou K; School of Nursing, Anhui University of Chinese Medicine, Hefei, 230001, Anhui, China. .; School of Public Health, Shantou University, Shantou, 515000, Guangdong, China. .
Źródło:
Molecular cancer [Mol Cancer] 2022 Oct 28; Vol. 21 (1), pp. 204. Date of Electronic Publication: 2022 Oct 28.
Typ publikacji:
Journal Article; Review
Język:
English
Imprint Name(s):
Original Publication: [London] : BioMed Central, c2002-
MeSH Terms:
Antioxidants*/pharmacology
Antioxidants*/therapeutic use
Brain Neoplasms*/drug therapy
Humans ; Neoplasm Recurrence, Local/drug therapy ; Oxidative Stress/physiology ; Reactive Oxygen Species/metabolism ; Carcinogenesis ; Tumor Microenvironment
References:
Br J Nutr. 2022 Jan 14;127(1):78-86. (PMID: 33750490)
J Neurosci. 2002 Sep 15;22(18):7923-30. (PMID: 12223545)
Biomarkers. 2012 Dec;17(8):671-91. (PMID: 22900535)
BMC Cancer. 2010 Sep 14;10:491. (PMID: 20840775)
J Pharmacol Sci. 2015 Jul;128(3):131-6. (PMID: 26154848)
Pharmacol Res. 2018 Apr;130:259-272. (PMID: 29496592)
Blood. 1999 Mar 1;93(5):1464-76. (PMID: 10029572)
Int J Oncol. 2015 Jul;47(1):35-42. (PMID: 25997921)
J Agric Food Chem. 2021 Jun 16;:. (PMID: 34133161)
EPMA J. 2021 Oct 06;12(4):559-587. (PMID: 34950252)
Recent Pat Anticancer Drug Discov. 2018;13(1):70-85. (PMID: 29189177)
J Neurooncol. 1996 Aug;29(2):121-8. (PMID: 8858516)
Carcinogenesis. 2008 Jan;29(1):62-9. (PMID: 17984113)
Antioxidants (Basel). 2017 Jul 22;6(3):. (PMID: 28737676)
Int J Mol Sci. 2020 Mar 23;21(6):. (PMID: 32210082)
Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11105-9. (PMID: 18678913)
BMC Cancer. 2017 Feb 4;17(1):99. (PMID: 28160777)
Oxid Med Cell Longev. 2018 Mar 22;2018:3734250. (PMID: 29854080)
Neoplasia. 2013 Jun;15(6):631-40. (PMID: 23730211)
Mol Pharmacol. 1996 Jun;49(6):1012-20. (PMID: 8649339)
Cancer Lett. 1985 Jun;27(2):221-4. (PMID: 4005831)
J Neurochem. 2007 Jul;102(2):522-38. (PMID: 17596214)
Biomedicines. 2020 Oct 19;8(10):. (PMID: 33086722)
Nutr Cancer. 2013;65(4):563-70. (PMID: 23659448)
Clin Cancer Res. 2009 Jun 15;15(12):4242-9. (PMID: 19509159)
Nutrients. 2020 Feb 12;12(2):. (PMID: 32059369)
Biomedicines. 2018 Sep 09;6(3):. (PMID: 30205595)
J Exp Clin Cancer Res. 2021 Oct 30;40(1):343. (PMID: 34717701)
Mol Ther Nucleic Acids. 2013 Oct 01;2:e126. (PMID: 24084846)
Oxid Med Cell Longev. 2021 Jun 26;2021:9924328. (PMID: 34257824)
Eur J Pharmacol. 2013 Oct 15;718(1-3):41-7. (PMID: 24070814)
J Control Release. 2018 May 10;277:89-101. (PMID: 29522834)
Neuroepidemiology. 2015;44(1):39-44. (PMID: 25720916)
Antioxidants (Basel). 2021 Jun 12;10(6):. (PMID: 34204594)
Semin Radiat Oncol. 2019 Jan;29(1):72-80. (PMID: 30573187)
PLoS One. 2014 Jan 08;9(1):e82331. (PMID: 24416140)
Future Med Chem. 2013 Oct;5(16):1967-91. (PMID: 24175747)
Curr Drug Metab. 2011 Jul;12(6):587-93. (PMID: 21434862)
Integr Cancer Ther. 2004 Dec;3(4):342-8. (PMID: 15523105)
J Oncol Pharm Pract. 2018 Jan;24(1):33-36. (PMID: 27903792)
J Natl Cancer Inst. 2011 Dec 7;103(23):1731-4. (PMID: 22100581)
Tumori. 2009 Nov-Dec;95(6):762-8. (PMID: 20210242)
Oncol Rep. 2016 Oct;36(4):2009-16. (PMID: 27498673)
Br J Nutr. 2008 Mar;99(3):667-73. (PMID: 17908366)
J Neurooncol. 2016 Jun;128(2):217-23. (PMID: 26983952)
DNA Cell Biol. 2013 Jun;32(6):292-7. (PMID: 23621850)
Discov Med. 2019 May;27(149):177-188. (PMID: 31361980)
Biol Chem. 2017 Sep 26;398(10):1095-1108. (PMID: 28384098)
Neurosurgery. 1997 Nov;41(5):1146-50; discussion 1151. (PMID: 9361070)
J Neurooncol. 2013 Aug;114(1):43-50. (PMID: 23754639)
J Neurooncol. 2015 Feb;121(3):469-77. (PMID: 25528634)
Brain Res. 2009 Apr 17;1266:130-8. (PMID: 19368804)
Clin Chim Acta. 2000 Jun;296(1-2):203-12. (PMID: 10807983)
Int J Mol Sci. 2020 Jan 09;21(2):. (PMID: 31936544)
Nutrients. 2020 Jun 17;12(6):. (PMID: 32560519)
Antioxid Redox Signal. 2014 Apr 1;20(10):1628-45. (PMID: 23706068)
Cell Death Dis. 2014 Oct 30;5:e1505. (PMID: 25356874)
Brain Pathol. 2009 Jan;19(1):121-31. (PMID: 19076777)
Front Oncol. 2019 Sep 27;9:942. (PMID: 31612107)
Cancer Res. 1996 Jul 15;56(14):3192-5. (PMID: 8764104)
Crit Rev Food Sci Nutr. 2018 Jun 13;58(9):1428-1447. (PMID: 28001084)
Biochem Pharmacol. 2012 Apr 15;83(8):1005-12. (PMID: 22138445)
Antioxidants (Basel). 2013 Nov 05;2(4):309-25. (PMID: 26784467)
Neurol Res. 2009 Apr;31(3):270-3. (PMID: 19040803)
Cancer. 2007 Sep 1;110(5):1083-95. (PMID: 17647244)
Front Nutr. 2022 Jan 20;8:812394. (PMID: 35127793)
Br J Cancer. 1996 Dec;74(12):1877-85. (PMID: 8980385)
J Cancer Res Ther. 2006 Jan-Mar;2(1):24-7. (PMID: 17998669)
Foods. 2017 Oct 22;6(10):. (PMID: 29065496)
Nutrients. 2015 Oct 28;7(11):8897-904. (PMID: 26516909)
Cancer Prev Res (Phila). 2012 May;5(5):701-5. (PMID: 22490437)
Nutr J. 2010 Jan 22;9:3. (PMID: 20096093)
Int J Mol Sci. 2016 Jun 22;17(6):. (PMID: 27338365)
Nutr Cancer. 2016 Aug-Sep;68(6):943-8. (PMID: 27340742)
Int J Mol Cell Med. 2021 Summer;10(3):163-181. (PMID: 35178355)
Nat Rev Clin Oncol. 2019 Aug;16(8):509-520. (PMID: 30733593)
J Cancer Res Clin Oncol. 1997;123(11-12):619-22. (PMID: 9620220)
Antioxidants (Basel). 2020 Aug 14;9(8):. (PMID: 32823815)
Neurochem Int. 2021 Oct;149:105118. (PMID: 34197897)
Nutrients. 2014 Nov 28;6(12):5453-72. (PMID: 25460513)
Nutrients. 2019 Jun 07;11(6):. (PMID: 31181639)
Front Genet. 2021 May 04;12:675780. (PMID: 34017357)
Integr Cancer Ther. 2018 Jun;17(2):210-216. (PMID: 28627256)
Colloids Surf B Biointerfaces. 2021 Aug;204:111778. (PMID: 33915380)
Nutr Cancer. 2016;68(1):48-57. (PMID: 26731169)
Biol Trace Elem Res. 2016 Aug;172(2):395-407. (PMID: 26706037)
Antioxidants (Basel). 2020 Nov 27;9(12):. (PMID: 33260826)
J Cancer. 2020 Apr 6;11(14):4047-4058. (PMID: 32368287)
Mol Pharmacol. 2007 Jul;72(1):29-39. (PMID: 17395690)
Oxid Med Cell Longev. 2019 Mar 12;2019:3061607. (PMID: 30984333)
Clin Chim Acta. 2003 Jan;327(1-2):103-7. (PMID: 12482624)
AAPS J. 2015 Mar;17(2):313-22. (PMID: 25466495)
Nutr Cancer. 2019;71(8):1241-1253. (PMID: 31007066)
Sci Transl Med. 2015 Oct 7;7(308):308re8. (PMID: 26446958)
Nutrients. 2019 Dec 30;12(1):. (PMID: 31905849)
Environ Toxicol Pharmacol. 2010 Jan;29(1):64-9. (PMID: 21787584)
Clin Cancer Res. 2019 Nov 15;25(22):6590-6597. (PMID: 31427282)
Cancer Cell. 2017 Apr 10;31(4):487-500.e8. (PMID: 28366679)
Handb Clin Neurol. 2012;104:23-34. (PMID: 22230432)
Science. 2020 Apr 10;368(6487):. (PMID: 32273439)
Oncol Rep. 2016 Jan;35(1):343-51. (PMID: 26498391)
Anticancer Res. 2011 Dec;31(12):4223-30. (PMID: 22199285)
Cell Physiol Biochem. 2011;28(2):219-28. (PMID: 21865729)
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):2941-3. (PMID: 11248007)
Tumour Biol. 2017 Feb;39(2):1010428317691680. (PMID: 28222667)
NMR Biomed. 2012 Nov;25(11):1234-44. (PMID: 22419606)
Carcinogenesis. 2010 Apr;31(4):533-42. (PMID: 19748925)
J Exp Clin Cancer Res. 2019 Jan 3;38(1):2. (PMID: 30606241)
FASEB J. 2015 Dec;29(12):4766-71. (PMID: 26253366)
Oxid Med Cell Longev. 2019 Mar 7;2019:4619865. (PMID: 30984336)
Int J Mol Sci. 2017 Dec 01;18(12):. (PMID: 29194365)
Clin Neurol Neurosurg. 2009 May;111(4):345-51. (PMID: 19117666)
Front Mol Biosci. 2021 Sep 01;8:649395. (PMID: 34540888)
Neuro Oncol. 2016 Feb;18(2):160-72. (PMID: 26180081)
Oncoscience. 2014 Jan 02;1(1):95-110. (PMID: 25593990)
J Neuroinflammation. 2005 Jun 01;2(1):12. (PMID: 15929797)
Int J Cancer. 1994 Nov 1;59(3):357-62. (PMID: 7927941)
Int J Cancer. 1999 Mar 31;81(1):20-3. (PMID: 10077146)
Neuro Oncol. 2008 Oct;10(5):709-15. (PMID: 18682580)
J Neurooncol. 2002 May;57(3):193-200. (PMID: 12125982)
J Int Med Res. 2009 Nov-Dec;37(6):1961-71. (PMID: 20146896)
Sci Rep. 2021 Apr 29;11(1):9318. (PMID: 33927267)
PLoS One. 2013 Oct 18;8(10):e78958. (PMID: 24205354)
Drug Des Devel Ther. 2021 Jun 28;15:2769-2781. (PMID: 34234410)
J Neurosurg. 1990 Apr;72(4):610-5. (PMID: 1690792)
PLoS One. 2017 May 2;12(5):e0176683. (PMID: 28464039)
Molecules. 2021 Apr 02;26(7):. (PMID: 33918290)
Cancer Causes Control. 2002 Sep;13(7):647-55. (PMID: 12296512)
Cancers (Basel). 2019 Apr 19;11(4):. (PMID: 31010244)
CNS Neurosci Ther. 2012 Jul;18(7):536-46. (PMID: 22530672)
Br J Cancer. 2020 May;122(11):1580-1589. (PMID: 32291392)
BMC Cancer. 2006 Jun 03;6:148. (PMID: 16749939)
Molecules. 2021 Jan 06;26(2):. (PMID: 33419120)
Biomolecules. 2020 Jan 19;10(1):. (PMID: 31963897)
Front Physiol. 2015 Dec 23;6:397. (PMID: 26779027)
Semin Cell Dev Biol. 2012 Sep;23(7):722-8. (PMID: 22504020)
Ageing Res Rev. 2013 Jan;12(1):376-90. (PMID: 23123177)
J Cell Physiol. 2019 May;234(5):5888-5903. (PMID: 29336479)
Int J Cancer. 2011 Dec 1;129(11):2720-31. (PMID: 21384342)
Oncol Lett. 2013 May;5(5):1583-1586. (PMID: 23761822)
Antioxidants (Basel). 2022 Feb 13;11(2):. (PMID: 35204257)
Annu Rev Pathol. 2011;6:345-64. (PMID: 21073338)
Front Cell Dev Biol. 2018 Oct 10;6:132. (PMID: 30364203)
J Neurochem. 2002 Feb;80(3):383-91. (PMID: 11905987)
Carcinogenesis. 1998 Jun;19(6):991-7. (PMID: 9667736)
Cancers (Basel). 2021 May 14;13(10):. (PMID: 34069106)
Comput Methods Programs Biomed. 2020 Nov;196:105706. (PMID: 32818721)
BMC Cancer. 2010 May 19;10:215. (PMID: 20482871)
Oxid Med Cell Longev. 2016;2016:5293284. (PMID: 27579153)
Biomed Pharmacother. 2021 Sep;141:111928. (PMID: 34323701)
Artif Cells Nanomed Biotechnol. 2018;46(sup3):S180-S191. (PMID: 30691320)
Genes Chromosomes Cancer. 2012 Oct;51(10):961-74. (PMID: 22736505)
Oncol Rep. 2013 Jun;29(6):2269-74. (PMID: 23588680)
EXCLI J. 2020 Aug 05;19:1120-1123. (PMID: 33088249)
Cancers (Basel). 2013 Aug 14;5(3):1049-71. (PMID: 24202333)
Nutrition. 2014 Nov-Dec;30(11-12):1272-8. (PMID: 25194962)
EBioMedicine. 2018 Oct;36:18-28. (PMID: 30279143)
Antioxidants (Basel). 2021 Dec 14;10(12):. (PMID: 34943091)
BMC Cancer. 2019 Oct 24;19(1):997. (PMID: 31651287)
Biomed Res Int. 2020 Dec 1;2020:6940953. (PMID: 33344645)
JAMA. 2015 Dec 15;314(23):2535-43. (PMID: 26670971)
Biomed Pharmacother. 2022 Feb;146:112442. (PMID: 35062053)
Cells. 2020 Mar 03;9(3):. (PMID: 32138190)
Stem Cell Rev Rep. 2016 Feb;12(1):140-55. (PMID: 26454429)
Cancer Lett. 2011 Nov 28;310(2):232-9. (PMID: 21803488)
Amino Acids. 2012 Jan;42(1):139-58. (PMID: 20454814)
Environ Mol Mutagen. 2009 Apr;50(3):247-65. (PMID: 19253339)
Biomolecules. 2021 Dec 07;11(12):. (PMID: 34944485)
Oxid Med Cell Longev. 2019 Dec 24;2019:7286737. (PMID: 31934267)
Front Oncol. 2019 Feb 04;9:41. (PMID: 30778375)
Oncol Rep. 2018 Aug;40(2):867-876. (PMID: 29989652)
Semin Cell Dev Biol. 2020 Feb;98:44-53. (PMID: 31176736)
Int J Oncol. 2021 Jun;58(6):. (PMID: 33955499)
Nutr Cancer. 2000;37(1):1-18. (PMID: 10965514)
BMC Cancer. 2013 Mar 22;13:147. (PMID: 23522185)
Free Radic Biol Med. 2015 Feb;79:281-91. (PMID: 25257256)
Cancer Sci. 2012 Apr;103(4):684-90. (PMID: 22192169)
Asian Pac J Cancer Prev. ;17(12):5303-5307. (PMID: 28125877)
Cancer Res. 2015 Aug 1;75(15):2999-3009. (PMID: 26045167)
Biomed Pharmacother. 2019 Apr;112:108612. (PMID: 30798142)
Food Sci Nutr. 2021 May 01;9(6):3308-3316. (PMID: 34136195)
Ann Epidemiol. 2009 Mar;19(3):161-71. (PMID: 19216998)
Mar Drugs. 2020 Sep 18;18(9):. (PMID: 32962073)
PLoS One. 2013 Jul 24;8(7):e68543. (PMID: 23894315)
Nature. 1981 Mar 19;290(5803):201-8. (PMID: 7010181)
J Pharm Sci. 2014 Jul;103(7):1945-1948. (PMID: 24801480)
Antioxidants (Basel). 2022 Jan 23;11(2):. (PMID: 35204096)
Sci Transl Med. 2014 Jan 29;6(221):221ra15. (PMID: 24477002)
Front Pharmacol. 2020 Mar 03;11:211. (PMID: 32194425)
Mol Carcinog. 2020 Apr;59(4):365-389. (PMID: 32017273)
Sci Rep. 2020 Aug 17;10(1):13899. (PMID: 32807842)
Carcinogenesis. 2000 May;21(5):909-14. (PMID: 10783311)
Cancer Treat Rev. 2020 Jul;87:102029. (PMID: 32408220)
Int J Oncol. 2017 Aug;51(2):467-477. (PMID: 28627598)
J Cancer Res Clin Oncol. 2021 Feb;147(2):403-409. (PMID: 33118056)
Neurol India. 2010 Jan-Feb;58(1):20-3. (PMID: 20228458)
Cytotechnology. 2018 Jun;70(3):1061-1073. (PMID: 29476302)
Neuro Oncol. 2001 Apr;3(2):73-81. (PMID: 11296483)
Int J Mol Med. 2018 Sep;42(3):1427-1435. (PMID: 29916532)
Free Radic Biol Med. 2009 Mar 15;46(6):719-30. (PMID: 19162177)
Free Radic Biol Med. 2007 Mar 15;42(6):787-97. (PMID: 17320761)
Food Chem Toxicol. 2017 Jul;105:322-336. (PMID: 28478100)
J Neurosci Res. 2010 Mar;88(4):877-86. (PMID: 19813266)
Oncotarget. 2016 Jun 14;7(24):37043-37053. (PMID: 27175595)
J Neurooncol. 2008 May;87(3):271-7. (PMID: 18217212)
Mol Cells. 2015 Nov;38(11):991-7. (PMID: 26537190)
Int J Mol Sci. 2020 Mar 12;21(6):. (PMID: 32178382)
Neurooncol Pract. 2015 Sep;2(3):122-126. (PMID: 26649185)
Oxid Med Cell Longev. 2016;2016:9324085. (PMID: 27807473)
Nutrients. 2021 Mar 16;13(3):. (PMID: 33809462)
Int J Mol Sci. 2020 Sep 28;21(19):. (PMID: 32998277)
Curr Neuropharmacol. 2019;17(4):342-351. (PMID: 29512467)
Am J Clin Nutr. 2007 Mar;85(3):877-86. (PMID: 17344512)
Cancer Manag Res. 2012;4:233-41. (PMID: 22904645)
Exp Ther Med. 2020 Feb;19(2):1511-1521. (PMID: 32010332)
J Pharmacol Sci. 2015 Dec;129(4):216-25. (PMID: 26698406)
Biomed Rep. 2020 Oct;13(4):32. (PMID: 32802329)
Molecules. 2017 May 25;22(6):. (PMID: 28587082)
Neuro Oncol. 2004 Jul;6(3):253-8. (PMID: 15279718)
Radiother Oncol. 2021 Feb;155:93-104. (PMID: 33129924)
Oxid Med Cell Longev. 2013;2013:972913. (PMID: 23766865)
Int J Mol Med. 2010 Aug;26(2):217-24. (PMID: 20596601)
Oncol Lett. 2012 Dec;4(6):1151-1157. (PMID: 23226794)
Exp Neurol. 1999 Aug;158(2):428-36. (PMID: 10415149)
Front Nutr. 2016 Apr 12;3:8. (PMID: 27148534)
Arch Med Sci. 2019 Aug 22;16(4):811-819. (PMID: 32542082)
Radiother Oncol. 2018 Aug;128(2):236-244. (PMID: 29784452)
Cancer Cell Int. 2021 Jul 21;21(1):391. (PMID: 34289841)
Br J Pharmacol. 2020 Mar;177(6):1382-1408. (PMID: 31626338)
Cancer Med. 2014 Aug;3(4):865-77. (PMID: 24898306)
Saudi Pharm J. 2018 Feb;26(2):177-190. (PMID: 30166914)
Chem Res Toxicol. 2022 May 16;35(5):880-889. (PMID: 35511042)
Mutat Res Genet Toxicol Environ Mutagen. 2015 Nov;793:86-95. (PMID: 26520377)
J Neuroimmunol. 2010 Dec 15;229(1-2):169-79. (PMID: 20826012)
Int J Neurosci. 2006 Aug;116(8):937-43. (PMID: 16861159)
PLoS One. 2017 Jan 12;12(1):e0169854. (PMID: 28081224)
Int J Neurosci. 2014 Dec;124(12):926-34. (PMID: 24617962)
Biomedicines. 2021 Mar 22;9(3):. (PMID: 33810154)
Free Radic Biol Med. 2006 Aug 1;41(3):464-72. (PMID: 16843827)
Chem Biol Interact. 2015 Dec 5;242:123-38. (PMID: 26408079)
Neurochem Int. 2021 Oct;149:105136. (PMID: 34274381)
Arch Neurol. 1999 Apr;56(4):439-41. (PMID: 10199332)
Front Cell Dev Biol. 2017 Apr 26;5:43. (PMID: 28491867)
Nanoscale Adv. 2019 Apr 16;1(6):2188-2207. (PMID: 36131972)
Neurosci Lett. 2000 Sep 22;291(3):179-82. (PMID: 10984636)
Cancer Epidemiol Biomarkers Prev. 1996 Aug;5(8):599-605. (PMID: 8824361)
Sci Rep. 2021 Jul 20;11(1):14766. (PMID: 34285315)
Molecules. 2020 Oct 23;25(21):. (PMID: 33113890)
Biomed Pharmacother. 2019 Jul;115:108783. (PMID: 31060003)
Antioxidants (Basel). 2018 Aug 30;7(9):. (PMID: 30200187)
Acta Clin Croat. 2019 Dec;58(4):726-736. (PMID: 32595258)
Turk Neurosurg. 2018;28(1):13-18. (PMID: 28191621)
Food Chem Toxicol. 2022 Aug;166:113205. (PMID: 35675861)
Cancers (Basel). 2020 Jun 08;12(6):. (PMID: 32521759)
Int J Biochem Cell Biol. 2005 Jun;37(6):1208-18. (PMID: 15778085)
Food Chem Toxicol. 2013 May;55:78-91. (PMID: 23291325)
Anticancer Res. 2012 Jul;32(7):2599-624. (PMID: 22753718)
Neurol Clin. 2016 Nov;34(4):981-998. (PMID: 27720005)
Front Neurol. 2020 Sep 17;11:1036. (PMID: 33041980)
Epilepsy Res. 2001 Aug;46(2):121-8. (PMID: 11463513)
Front Pharmacol. 2019 Dec 06;10:1336. (PMID: 31866857)
Free Radic Biol Med. 2012 Apr 15;52(8):1486-93. (PMID: 22342518)
J Cancer. 2019 Aug 19;10(19):4679-4688. (PMID: 31528233)
Arch Physiol Biochem. 2003 Dec;111(5):455-9. (PMID: 16026034)
Cell Physiol Biochem. 2010;25(6):767-74. (PMID: 20511723)
Int J Mol Med. 2012 Nov;30(5):1081-6. (PMID: 22960751)
Biosci Trends. 2011;5(1):30-7. (PMID: 21422598)
Mol Nutr Food Res. 2019 Nov;63(22):e1900629. (PMID: 31441212)
Contributed Indexing:
Keywords: Antioxidant; Brain tumor; Chemopreventive role; Chemotherapy; Dietary antioxidants; Gene mutation; Glioblastoma; Glioma; Metabolic reprogramming; Oxidative stress
Substance Nomenclature:
0 (Antioxidants)
0 (Reactive Oxygen Species)
Entry Date(s):
Date Created: 20221029 Date Completed: 20221101 Latest Revision: 20221221
Update Code:
20240105
PubMed Central ID:
PMC9615186
DOI:
10.1186/s12943-022-01668-9
PMID:
36307808
Czasopismo naukowe
Brain cancer is regarded among the deadliest forms of cancer worldwide. The distinct tumor microenvironment and inherent characteristics of brain tumor cells virtually render them resistant to the majority of conventional and advanced therapies. Oxidative stress (OS) is a key disruptor of normal brain homeostasis and is involved in carcinogenesis of different forms of brain cancers. Thus, antioxidants may inhibit tumorigenesis by preventing OS induced by various oncogenic factors. Antioxidants are hypothesized to inhibit cancer initiation by endorsing DNA repair and suppressing cancer progression by creating an energy crisis for preneoplastic cells, resulting in antiproliferative effects. These effects are referred to as chemopreventive effects mediated by an antioxidant mechanism. In addition, antioxidants minimize chemotherapy-induced nonspecific organ toxicity and prolong survival. Antioxidants also support the prooxidant chemistry that demonstrate chemotherapeutic potential, particularly at high or pharmacological doses and trigger OS by promoting free radical production, which is essential for activating cell death pathways. A growing body of evidence also revealed the roles of exogenous antioxidants as adjuvants and their ability to reverse chemoresistance. In this review, we explain the influences of different exogenous and endogenous antioxidants on brain cancers with reference to their chemopreventive and chemotherapeutic roles. The role of antioxidants on metabolic reprogramming and their influence on downstream signaling events induced by tumor suppressor gene mutations are critically discussed. Finally, the review hypothesized that both pro- and antioxidant roles are involved in the anticancer mechanisms of the antioxidant molecules by killing neoplastic cells and inhibiting tumor recurrence followed by conventional cancer treatments. The requirements of pro- and antioxidant effects of exogenous antioxidants in brain tumor treatment under different conditions are critically discussed along with the reasons behind the conflicting outcomes in different reports. Finally, we also mention the influencing factors that regulate the pharmacology of the exogenous antioxidants in brain cancer treatment. In conclusion, to achieve consistent clinical outcomes with antioxidant treatments in brain cancers, rigorous mechanistic studies are required with respect to the types, forms, and stages of brain tumors. The concomitant treatment regimens also need adequate consideration.
(© 2022. The Author(s).)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies